Ouro Medicines

Gilead Sciences Gains an Opportunity for Immune System Reset With $1.7B Ouro Acquisition

Gilead Sciences is acquiring Ouro Medicines, a startup developing T cell engagers for a range of autoimmune diseases. Separately, Gilead is negotiating a deal with Galapagos to share in the development and potential commercialization of the Ouro drug.

By Frank Vinluan

BioPharma, Pharma

Immunology Startup Ouro Sets Out With $120M for Drugs That Reset the Immune System

Ouro Medicines’ drugs deplete disease-driving immune cells, allowing the immune system to reset with naïve cells that don’t attack the body. Monograph Capital founded the startup in partnership with GSK.

By Frank Vinluan

The Mechanics of a More Connected Healthcare Ecosystem [Video]

Arbiter’s Anjali Jameson on hospital and payer alignment.

By Arbiter and MedCity News